NuVasive receives clearance for XLIF in Japan as Class III medical device: 5 key notes Featured

Written by  Laura Dyrda | Thursday, 29 December 2016 10:12
Social sharing

The Japanese Ministry of Health, Labour and Welfare granted NuVasive approval for the instruments used in the eXtreme Lateral Interbody Fusion procedure.

Here are five quick notes:


1. The MHLW classified the technology as a Class III medical device. The XLIF procedure was originally approved in August 2011 as a Class II device and additional dilator sizes were approved in January 2014.


2. The company submitted the dilator and associated components for reclassification as a Class III medical device and since that time surgeons temporarily stopped performing the XLIF procedure in Japan.


3. The surgeons will resume performing XLIF in the first quarter of 2017. In connection with the MHLW approval, NuVasive will provide additional surgeons with experience performing the XLIF procedures and the surgeries will be performed at approved hospitals.


4. XLIF is a minimally invasive surgical procedure where surgeons use proprietary neuromonitoring and an integrated portfolio of instruments and implants to correct a range of spinal pathologies.


5. There are more than 350 peer-reviewed journal articles around the world examining XLIF and outcomes 11 years after surgery. Surgeons have performed XLIF on more than 150,000 patients around the world and 5,000 operations in Japan since 2013.


More articles on spine devices:
Stryker, Mazor & more: 10 device company key notes
Fuse Medical raises money, changes leadership team—Christopher Reed to become CEO
Precision Spine earns FDA 510(k) clearance AccuFit lateral plate system

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.